Inoviq Ltd · ASX:IIQ
Inoviq — Investor Presentation (August 2023)
28 slides from Inoviq's investor presentation, Aug 1, 2023
Slide 1: Accelerating momentum in 2023
Accelerating momentum in 2023 For personal use only ASX: IIQ | 1 August 2023
Slide 2: Disclaimer
Disclaimer For personal use only This presentation has been prepared by INOVIQ Limited (“INOVIQ” or the “Company”) Actual results, performance or achievements could be significantly different from those based on information available to it as at the date of this presentation. This presentation expre
Slide 3: About INOVIQ Ltd
About INOVIQ Ltd For personal use only INOVIQ’s mission is to develop next-generation precision diagnostics and exosome solutions that transform the diagnosis and treatment of cancer and other diseases to improve patient outcomes and save lives $ Precision Disruptive Deep Compelling Commercial Partn
Slide 4: Company snapshot
Company snapshot For personal use only INOVIQ snapshot Financial information (ASX:IIQ) • Founded 2016 as a single-asset diagnostics company focused on earlier cancer detection Ordinary shares2 92,018,702 • Multiple acquisitions and in-licensing to expand technology portfolio Listed options2 5,909,96
Slide 5: Unmet need for early cancer detection
Unmet need for early cancer detection For personal use only Unmet need 120% 5-year survival rates by stage at diagnosis1 • Unmet needs for non-invasive, accurate and reliable 99% 98%100% 100% 96% diagnostic tests for earlier cancer detection and monitoring 90% 93% • Earlier detection improves treatm
Slide 6: Products and pipeline | Expanding EXO-NET tools and diagnostics portfolio
Products and pipeline | Expanding EXO-NET tools and diagnostics portfolio use only PRODUCT INDICATION USE RESEARCH ASSAY CLINICAL MARKET DEVELOPMENT DEVELOPMENT hTERT1 Bladder Cancer Adjunct to cytology IVD-Class 1 USA tools/Dx SubB2M Dx SubB2M-BC Breast Cancer Monitoring LDT Dec-23 SubB2M-OC Ovaria
Slide 7: SubB2M diagnostics
SubB2M diagnostics For personal use only Improved SubB2M-based cancer diagnostic tests for cancer detection and monitoring neuraminic acid 7
Slide 8: SubB2M technology platform
SubB2M technology platform For personal use only Scientific rationale • Cancer cells have a distinct feature of adding different sugar molecules to the proteins they produce, which sets them apart from normal cells • One such sugar molecule commonly found in cancer cells is Neu5Gc • SubB2M preferent
Slide 9: SubB2M/CA15-3 Breast Cancer test | improved BC monitoring
SubB2M/CA15-3 Breast Cancer test | improved BC monitoring For personal use only Clinical-stage and progressing towards market-ready for LDT partnering by Dec 2023 • #1 cancer in women Key milestones Breast cancer • 2.3m new cases of breast cancer worldwide pa1 • 7.8m 5-year survivors1 Feasibility Co
Slide 10: SubB2M/CA15-3 Breast Cancer test: Study BC04
SubB2M/CA15-3 Breast Cancer test: Study BC04 For personal use only Table 1: SubB2M/CA15-3 and comparator CA15-3 test performance summary Study objectives Breast Cancer All Stages SubB2M Comparator AUC 0.93 0.70 • To evaluate the clinical performance of the sensitivity 81% 37% SubB2M/CA15-3 test acro
Slide 11: SubB2M/CA15-3 breast cancer test | data
SubB2M/CA15-3 breast cancer test | data For personal use only Data from a 483-sample retrospective, case-control, clinical validation study demonstrated the SubB2M/CA15-3 breast cancer test significantly outperformed a leading approved CA15-3 test across all stages of breast cancer1 ✓ SubB2M/CA15-3
Slide 12: SubB2M/CA15-3 Breast Cancer test: Study BC-004 next steps
SubB2M/CA15-3 Breast Cancer test: Study BC-004 For personal use only Next Steps • Evaluate the performance of the SubB2M/CA15-3 test for monitoring treatment response and disease recurrence • Does SubB2M/CA15-3 detect changes in tumor growth earlier than CA15-3 (and other biomarkers) and thus better
Slide 13: SubB2M/CA125 Ovarian Cancer Test | improved OC monitoring
SubB2M/CA125 Ovarian Cancer Test | improved OC monitoring For personal use only Progressing towards clinical validation • #8 cancer in women Key milestones Ovarian cancer • 314k new cases of ovarian cancer worldwide pa1 • 823k 5-year survivors1 Feasibility Completed • No approved test for early dete
Slide 14: Pipeline products: EXO diagnostics
Pipeline products: EXO diagnostics For personal use only EXO-NET exosome isolation for biomarker discovery and diagnostic development 14
Slide 15: Exosomes | Diagnostic and therapeutic potential
Exosomes | Diagnostic and therapeutic potential For personal use only • Exosomes are released by cells and perform key roles in intercellular communication, immune regulation and pathogenesis • Diseases elicit changes in the release of exosomes and their molecular cargo (DNA, RNA and proteins) • Exo
Slide 16: EXO-NET | Exosome isolation tools
EXO-NET® | Exosome isolation tools For personal use only • EXO-NET is an immunoaffinity magnetic bead-based isolation system • EXO-NET pan-exosome capture is a research use only (RUO) tool for exosome isolation from plasma, serum, urine, saliva and cell-conditioned medium • Meets unmet need for fast
Slide 17: EXO-NET delivers fast, efficient and scalable exosome isolation
EXO-NET delivers fast, efficient and scalable exosome isolation For personal use only High Speed Easy and convenient workflow with EV capture in 15-40 minutes via manual or automated processing High Specificity EV-surface antigen capture High Purity Reduced co-isolation of contaminants & high enrich
Slide 18: EXO-NET | Exosome services
EXO-NET | Exosome services For personal use only CUSTOMISED EXOSOME BIOMARKER DIAGNOSTICS EXO-NET TOOLS ISOLATION DISCOVERY DEVELOPMENT Design custom EXO-NET EV isolation using our Biomarker discovery EV-based clinical tools using ligands for EXO-NET powered, fully- services to identify, diagnostic,
Slide 19: EXO-Ovarian Cancer Test | World-first exosome-based screening test
EXO-Ovarian Cancer Test | World-first exosome-based screening test1,2,3 For personal use only Moving towards clinical validation • #8 cancer in women Key milestones Ovarian cancer • 314k new cases of ovarian cancer worldwide pa4 • 823k 5-year survivors4 Feasibility Completed • No approved test for e
Slide 20: EXO-Ovarian Cancer Test | data and plans
EXO-Ovarian Cancer Test | data and plans For personal use only EXO-NET isolated EV ovarian cancer diagnostic Stage I & II Ovarian Cancer (n=465) ✓ • OC-ED003 Study: retrospective case-control Feasibility Study in 97-plasma samples AA OCRF-7 OCRF-7 B B CA-125 establishing EXO-NET superiority over SEC
Slide 21: Commercialisation and milestones
Commercialisation and milestones For personal use only 21
Slide 22: Market potential | Screening and monitoring tests
Market potential | Screening and monitoring tests For personal use only Eligible screening Eligible monitoring Statistics1 Global Market size4,5 population2 population3 11.5 4.0 Ovarian cancer incidence 188.3 52,638 60.4 6 Ovarian 119m 367k $1.9b 54.7 GLOBAL Dx cancer 167.3 MARKET Ovarian cancer pre
Slide 23: SubB2M | Go-to-market strategy
SubB2M | Go-to-market strategy For personal use only Build clinical data Commercialisation Geographic Sell first as an LDT IVD development IVD partnering package paths roll-out via a partner Partner with major Build clinical Market as Lab diagnostic evidence in the Developed Test Commence selling co
Slide 24: CY2023 milestones and catalysts
CY2023 milestones and catalysts For personal use only SubB2M/CA15-3 BC and EXO-NET OC programs moving towards key inflection points H2 FY2023 H1 FY2024 ✓ Results SubB2M/CA15-3 breast cancer study ✓ EXO-NET co-marketing agreement with Promega ✓ Results SubB2M/CA15-3 BC clinical validation study (n=48
Slide 25: Summary | Next generation diagnostic solutions advancing towards key milestones
Summary | Next generation diagnostic solutions advancing towards key milestones For personal use only 1 Innovative 2 Patented 3 Strong 4 Compelling Company Technology Pipeline Results Focused on next-gen diagnostic Proprietary SubB2M & NETs Deep pipeline Data for SubB2M and exosome- and exosome solu
Slide 26: Contacts
Contacts For personal use only Dr Leearne Hinch Dr Gregory Rice Chief Executive Officer Chief Scientific Officer e. lhinch@inoviq.com e. grice@inoviq.com Mark Edwards Chief Financial Officer and Company Secretary e. medwards@inoviq.com INOVIQ Ltd, 23 Normanby Road, Notting Hill, VIC 3168 Australia 2
Slide 27: Board and Management | Healthcare, corporate & commercial experience
Board and Management | Healthcare, corporate & commercial experience For personal use only DR GEOFF CUMMING MAX JOHNSTON PHILIP POWELL Non-Executive Chairman Non-Executive Director Non-Executive Director Healthcare and biotechnology director with Healthcare industry director and Healthcare industry
Slide 28: Strong IP portfolio covering technologies and applications
Strong IP portfolio covering technologies and applications For personal use only Patent Family Title Granted Pending Expiry • Broad patent portfolio SubB2M protecting IIQ’s exosome PCT/AU2017/051230 Subtilase cytotoxin B subunit mutant AU, JP, US BR, CA, CN, EP, IN, KR, 2037 platform, biomarker (WO2